glp-1 weight loss drugs news today U.S. Obesity Rate Drops as Use of Surges | National GLP-1 Agonists Weight Loss Drugs
Description
However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors
Sources for Figure 218
Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020
ProAct Pharmacy Benefit Management Solutions
